WALTHAM,
Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of
Syndax, as well as members of the Syndax management team, will
participate in the following upcoming investor conferences:
- Guggenheim's Inaugural Healthcare Innovation Conference
in Boston, MA with a fireside chat
on Wednesday, November 13, 2024, at
1:30 p.m. ET
- UBS Global Healthcare Conference in Ranchos Palos
Verdes, CA with a fireside chat on Thursday,
November 14, 2024, at 10:15 a.m.
ET / 7:15 a.m. PT
- Stifel 2024 Healthcare Conference in New York, NY with a fireside chat on
Monday, November 18, 2024, at
1:50 p.m. ET
- Jefferies London Healthcare Conference in London, UK, November
20-21, 2024
A live webcast of the fireside chats will be available in the
Investor section of the Company's website at www.syndax.com, where
a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a selective menin inhibitor, and Niktimvo™
(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks
the colony stimulating factor 1 (CSF-1) receptor. Fueled by our
commitment to reimagining cancer care, Syndax is working to unlock
the full potential of its pipeline and is conducting several
clinical trials across the continuum of treatment. For more
information, please visit www.syndax.com/ or follow the Company on
X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-november-investor-conferences-302293915.html
SOURCE Syndax Pharmaceuticals, Inc.